The lack of suitable tumor samples from well annotated clinical trials and the resulting reliance on mouse xenograft and in vitro cancer models has precluded the identification of clinically relevant predictive biomarkers for mTOR inhibitors and anti-angiogenic drugs in RCC and other solid tumors [39]. Here, MTOR is linked to renal cell carcinoma.